• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Aspira Women's Health Inc. (Amendment)

    1/13/22 4:48:33 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $AWH alert in real time by email
    SC 13D/A 1 brhc10032806_sc13da.htm SC 13D/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D
    Under the Securities Exchange Act of 1934
    (Amendment No. 14)*
     
    Aspira Women's Health Inc.
    (Name of Issuer)
     
    Common Stock, Par Value $0.001 Per Share
    (Title of Class of Securities)
     
    04537Y109
    (CUSIP Number)
     
    Tanya Schuler Sharman
    100 N. Field Drive, Suite 360
    Lake Forest, Illinois 60045
    (224) 880-1210
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     
    November 29, 2021
    (Date of Event which Requires Filing of this Statement)
     
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
     
    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



     
    SCHEDULE 13D
     
    CUSIP No: 04537Y109
     
    Page  2 of 5 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Tanya Schuler Sharman
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    5,943,881
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    5,943,881
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    5,943,881
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    5.3% (1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     
     
    1.          This percentage is based on a total of 112,126,549 Shares outstanding as of November 8, 2021, as reported by the Issuer in its Form 10-Q filed by the Company with the Securities and Exchange Commission on November 10, 2021


     
    SCHEDULE 13D
     
    CUSIP No: 04537Y109
     
    Page  3 of 5 Pages

    1
    NAMES OF REPORTING PERSONS    
    Tanya Eva Schuler Trust
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Illinois
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    5,943,881
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    5,943,881
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    5,943,881
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    5.3% (1)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
     
    1.          This percentage is based on a total of 112,126,549 Shares outstanding as of November 8, 2021, as reported by the Issuer in its Form 10-Q filed by the Company with the Securities and Exchange Commission on November 10, 2021.


     
    SCHEDULE 13D
     
    CUSIP No: 04537Y109
     
    Page  4 of 5 Pages
    Item 1.
    Security and Issuer
     
    Item 1 of the Schedule 13D is hereby amended and supplemented as follows:
     
    This Amendment No. 14 to Schedule 13D (“Amendment No. 14”) is being filed by the undersigned, pursuant to §240.13d-2(a), to amend and supplement the Schedule 13D filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 23, 2013, (the “Initial Schedule 13D”), as amended by Amendment No. 1 filed on December 29, 2014, Amendment No. 2 filed on February 11, 2015, Amendment No. 3 filed on March 23, 2015, Amendment No. 4 filed on April 28, 2015, Amendment No. 5 filed on July 21, 2015, Amendment No. 6 filed on February 2, 2017, and Amendment No. 7 filed on September 5, 2017, Amendment No. 8 filed on April 19, 2018, Amendment No. 9 filed on June 25, 2018, Amendment No. 10 filed on July 02, 2019, Amendment No. 11 filed on June 12, 2020, Amendment No. 12 filed on July 06, 2020, and Amendment No. 13 filed on February 10, 2021 (collectively, the “Schedule 13D”), with respect to the common stock, par value $0.001 per share (the “Shares”), of Aspira Women's Health Inc. (the “Issuer”), whose principal executive offices are located at 12117 Bee Caves Road, Building Three, Suite 100, Austin, Texas 78738.
     
    Item 4.
    Purpose of Transaction
     
    Item 4 of the Schedule 13D is hereby amended and supplemented as follows:
     
    On November 29, 2021, a gift of 567,981 Shares was completed by the Schuler Descendants Trust, for which Tanya Sharman serves as co-trustee, to Schuler Grandchildren LLC.  Subsequent to this gift, Schuler Descendants Trust no longer owns any Shares.
     
    Item 5.
    Interest in Securities of the Issuer
     
    Item 5(a)-(c) of the Schedule 13D is hereby amended and supplemented as follows:
     
    (a, b) As of the date hereof, Tanya Sharman may be deemed to beneficially own 5,943,881 Shares, representing approximately 5.3% of the Shares outstanding. This amount consists of 5,943,881 Shares held by the Tanya Trust.
     
    As of the date hereof, Tanya Trust may be deemed to beneficially own 5,943,881 Shares, representing approximately 5.3% of the Shares outstanding.
     
    The foregoing beneficial ownership percentages are based on a total of 112,126,549 Shares outstanding as of November 8, 2021, as reported by the Issuer in its Form 10-Q filed by the Company with the Securities and Exchange Commission on November 10, 2021.
     
    As sole trustee of the Tanya Trust, Tanya Sharman and the Tanya Trust share the power to vote or to direct the vote, and the power to dispose or to direct the disposition of, the Shares held by the Tanya Trust.
     
    (c) Other than the gift of Shares described in Item 4 of this Amendment No. 14, no transactions in the Shares have been effected by the Reporting Persons within the past 60 days.
     

     
    SCHEDULE 13D
     
    CUSIP No: 04537Y109
     
    Page  5 of 5 Pages
    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
    Tanya Schuler Sharman
     
    /s/ Tanya Schuler Sharman
       
     
    Tanya Eva Schuler Trust
     
    /s/ Tanya Schuler Sharman
     
    Name: Tanya Schuler Sharman
     
    Title: Trustee
    January 13, 2022
     
    Attention: Intentional misstatements or omissions of act constitute federal violations (see 18 U.S.C. 1001).



    Get the next $AWH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AWH

    DatePrice TargetRatingAnalyst
    1/12/2022$4.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $AWH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aspira Women's Health Announces the Appointment of Mike Buhle as SVP of Commercial Operations

    Interim CFO John Kallassy to Depart January 10 AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mike Buhle as SVP of Commercial Operations.Mr. Buhle has over 25 years of experience driving commercial growth and new product launches in the diagnostics and life science tools domains, working for start-up, scale-up, and established businesses. He brings hands-on leadership experience in clinical diagnostics specializing in precision medicine and patient outcomes in oncology, rare dise

    1/10/25 8:00:00 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Aspira Women's Health Announces Appointment of Dr. Sandra Milligan as Interim CEO

    AUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, Chief Executive Officer (CEO) and Board member, will be departing the Company to focus on a family health matter. Aspira's President Dr. Sandra Milligan will step into the role of interim CEO while a nationwide search of internal and external candidates is conducted. Ms. Sandford's departure will be effective immediately. She will remain as a consultant to ensure a seamless transition. "The Board thanks Nicole for the outst

    12/16/24 8:45:00 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Aspira Women's Health Successfully Reaches the First Milestone of the ARPA-H $10 Million Award

    AUSTIN, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the successful completion of the first development milestone of its Advanced Research Projects Agency for Health (ARPA-H) award. As a result, Aspira has received a $2 million cash payment under the terms of the related agreement. ARPA-H's Sprint for Women's Health was created to address critical unmet challenges in women's health, champion transformative innovations, and tackle health conditions that uniquely or disproportionately affect women. As previously a

    12/3/24 8:00:00 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AWH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Fraser John D claimed ownership of 841,558 shares (SEC Form 3)

    3 - Aspira Women's Health Inc. (0000926617) (Issuer)

    4/28/25 7:19:40 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 3 filed by new insider Hundorfean Cynthia D

    3 - Aspira Women's Health Inc. (0000926617) (Issuer)

    4/24/25 9:41:23 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Director Vos Ellen O'Connor converted options into 5,313 shares, increasing direct ownership by 8% to 68,677 units (SEC Form 4)

    4 - Aspira Women's Health Inc. (0000926617) (Issuer)

    4/2/25 8:23:47 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AWH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald resumed coverage on Aspira Women's Health with a new price target

    Cantor Fitzgerald resumed coverage of Aspira Women's Health with a rating of Overweight and set a new price target of $4.00

    1/12/22 7:53:25 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Truist Securities initiated coverage on Aspira Womens Health with a new price target

    Truist Securities initiated coverage of Aspira Womens Health with a rating of Buy and set a new price target of $12.00

    3/29/21 7:32:28 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Cantor Fitzgerald initiated coverage on Aspira Womens Health with a new price target

    Cantor Fitzgerald initiated coverage of Aspira Womens Health with a rating of Overweight and set a new price target of $10.00

    1/29/21 6:12:39 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AWH
    SEC Filings

    View All

    Amendment: SEC Form S-1/A filed by Aspira Women's Health Inc.

    S-1/A - Aspira Women's Health Inc. (0000926617) (Filer)

    4/30/25 8:10:19 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form DEFR14A filed by Aspira Women's Health Inc.

    DEFR14A - Aspira Women's Health Inc. (0000926617) (Filer)

    4/22/25 4:05:41 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Aspira Women's Health Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - Aspira Women's Health Inc. (0000926617) (Filer)

    4/16/25 5:07:30 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AWH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Schuler Jack W bought 6,536 shares (SEC Form 4)

    4 - Aspira Women's Health Inc. (0000926617) (Issuer)

    7/11/24 5:15:45 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Large owner Schuler Jack W bought 28,500 shares (SEC Form 4)

    4 - Aspira Women's Health Inc. (0000926617) (Issuer)

    6/18/24 4:12:21 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Sandford Nicole bought $22,973 worth of shares (9,493 units at $2.42), increasing direct ownership by 16% to 70,596 units (SEC Form 4)

    4 - Aspira Women's Health Inc. (0000926617) (Issuer)

    6/3/24 5:30:57 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AWH
    Leadership Updates

    Live Leadership Updates

    View All

    Aspira Women's Health Announces Appointment of Dr. Sandra Milligan as Interim CEO

    AUSTIN, Texas, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, Chief Executive Officer (CEO) and Board member, will be departing the Company to focus on a family health matter. Aspira's President Dr. Sandra Milligan will step into the role of interim CEO while a nationwide search of internal and external candidates is conducted. Ms. Sandford's departure will be effective immediately. She will remain as a consultant to ensure a seamless transition. "The Board thanks Nicole for the outst

    12/16/24 8:45:00 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Aspira Women's Health Selected as a Spoke for the Investor Catalyst Hub

    AUSTIN, Texas, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it was selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H). Based in the Greater Boston area and managed by VentureWell, the Investor Catalyst Hub seeks to accelerate the commercialization of groundbreaking and accessible biomedical solutions. It utilizes an innovative hub-and-spoke model designed to reach a wide range of

    9/5/24 8:00:00 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Aspira Women's Health Appoints Mr. John Ragard to its Board of Directors

    AUSTIN, Texas, July 29, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of Mr. John Ragard to its Board of Directors. Mr. Ragard is an accomplished executive with extensive experience successfully managing several billion-dollar portfolios over his career. "We are pleased to welcome John to our Board of Directors," said Ms. Jannie Herchuk, Chairwoman of the Board at Aspira Women's Health. "John brings a wealth of experience and a keen understanding of Wall Street, having been a successful money manager for the past

    7/29/24 9:00:00 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AWH
    Financials

    Live finance-specific insights

    View All

    Aspira Women's Health Reports Selected Third Quarter 2024 Financial Results

    Q3 2024 OvaSuiteSM revenue of $2.3 million and volume of 6,001 units Cash utilization for the third quarter was $2.9 million, a decrease of 12% compared to the second quarter of 2024 Full year 2024 cash guidance reconfirmed as $13.0-$14.5 million Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported selected financial results for the third quarter ended September 30, 2024. "OvaWatch® product volume, which we believe is the most import

    11/14/24 8:00:00 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Aspira Women's Health to Announce Third Quarter Earnings Results and Host a Conference Call on Thursday, November 14, 2024

    AUSTIN, Texas, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three and nine months ended September 30, 2024, on Thursday, November 14, 2024. Management will also host a conference call at 8:30 am ET to discuss financial results and provide a corporate update. Details of the call are as follows: Conference Call & Webcast Details:Date:Thursday, November 14, 2024Time:8:30 am ETToll Free:877-545-0320International:973-528-0002Access Code:436613Webcast:R

    11/4/24 8:00:00 AM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Aspira Women's Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 12

    AUSTIN, Texas, July 31, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that the Company will report its financial results for the three months ended June 30, 2024, on Monday, August 12, 2024. Management will also host a conference call at 4:30 p.m. Eastern Time to discuss financial results and provide a corporate update. Details for the call are as follows: Conference Call & Webcast Details:Date: Monday, August 12, 2024Time: 4:30 p.m. ETToll Free:877-407-4018Webcast:Click HERE   A replay of the webcast will also be

    7/31/24 4:05:00 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AWH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Aspira Women's Health Inc.

    SC 13G - Aspira Women's Health Inc. (0000926617) (Subject)

    11/14/24 3:23:57 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13D/A filed by Aspira Women's Health Inc.

    SC 13D/A - Aspira Women's Health Inc. (0000926617) (Subject)

    7/11/24 5:14:26 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13D/A filed by Aspira Women's Health Inc.

    SC 13D/A - Aspira Women's Health Inc. (0000926617) (Subject)

    6/18/24 4:13:01 PM ET
    $AWH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care